FinscoFinsco

CG Oncology (US.CGON)

Capital Allocation Audit · Period: 2021 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CGON · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.5%→
ROE-5.5%↓
Cash Conversion-→
D/E Ratio0.01↓
Gross Margin-173.5%↓
US.CGON (CG Oncology) | YoY: 2026 Q1 vs 2025 Q1


Metric             Value  YoY
-----------------------------
FCF Conversion    100.5%    →
ROE                -5.5%    ↓
Cash Conversion        -    →
D/E Ratio           0.01    ↓
Gross Margin     -173.5%    ↓
Key Metrics
US.CGON (CG Oncology) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
-----------------------------
FCF Conversion 100.5% →
ROE -5.5% ↓
Cash Conversion - →
D/E Ratio 0.01 ↓
Gross Margin -173.5% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies